Equities analysts expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to announce earnings of $1.11 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Eagle Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $1.10 and the highest estimate coming in at $1.12. Eagle Pharmaceuticals posted earnings of $1.22 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 9%. The business is expected to issue its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $4.00 per share for the current year, with EPS estimates ranging from $3.93 to $4.07. For the next fiscal year, analysts forecast that the firm will post earnings of $4.97 per share, with EPS estimates ranging from $4.43 to $5.52. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.15. Eagle Pharmaceuticals had a net margin of 13.81% and a return on equity of 19.71%. The company had revenue of $59.30 million during the quarter, compared to the consensus estimate of $51.78 million.
NASDAQ:EGRX traded up $0.85 during trading hours on Friday, hitting $79.34. The stock had a trading volume of 229,356 shares, compared to its average volume of 236,253. The company has a quick ratio of 5.66, a current ratio of 4.22 and a debt-to-equity ratio of 0.22. Eagle Pharmaceuticals has a 1-year low of $48.84 and a 1-year high of $85.66. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of 23.54 and a beta of 1.43.
Several institutional investors have recently added to or reduced their stakes in EGRX. Millennium Management LLC purchased a new position in shares of Eagle Pharmaceuticals during the 4th quarter valued at approximately $1,113,000. MetLife Investment Advisors LLC purchased a new position in shares of Eagle Pharmaceuticals during the 4th quarter valued at approximately $218,000. Wells Fargo & Company MN boosted its stake in shares of Eagle Pharmaceuticals by 14.4% during the 1st quarter. Wells Fargo & Company MN now owns 23,287 shares of the specialty pharmaceutical company’s stock valued at $1,228,000 after buying an additional 2,936 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of Eagle Pharmaceuticals by 17.7% during the 1st quarter. Alps Advisors Inc. now owns 8,582 shares of the specialty pharmaceutical company’s stock valued at $452,000 after buying an additional 1,288 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its stake in shares of Eagle Pharmaceuticals by 13.8% during the 1st quarter. New York State Teachers Retirement System now owns 9,915 shares of the specialty pharmaceutical company’s stock valued at $522,000 after buying an additional 1,200 shares during the last quarter.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Featured Article: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.